The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Development trends for human monoclonal antibody therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Ziegler, E. J., Fisher, C. J., Sprung, C. L., Straube, R. C., Sadoff, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P., Dellinger, R. P., Teng, N. N. H., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240701 · Cited by 1,611
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Making antibody fragments using phage display libraries
Clackson, T., Hoogenboom, H. R., Griffiths, A. D., & Winter, G. (1991) · Nature · doi:10.1038/352624a0 · Cited by 1,203
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., & Johnson, K. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-309 · Cited by 1,027
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Cited by
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Contribution of Organofluorine Compounds to Pharmaceuticals
Inoue, M., Sumii, Y., & Shibata, N. (2020) · ACS Omega · doi:10.1021/acsomega.0c00830 · Cited by 1,944
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Monoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Liu, J. K. H. (2014) · Annals of Medicine & Surgery · doi:10.1016/j.amsu.2014.09.001 · Cited by 515
Recent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery
Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., Zhang, L., Song, Y., Liu, X., Zhang, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr797 · Cited by 480
The Increasingly Human and Profitable Monoclonal Antibody Market
Grilo, A. L., & Mantalaris, A. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.05.014 · Cited by 462
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Monoclonal antibody therapeutics: history and future
Buss, N. A., Henderson, S. J., McFarlane, M., Shenton, J. M., & de Haan, L. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.08.001 · Cited by 434
Diversity-oriented synthesis: producing chemical tools for dissecting biology
O' Connor, C. J., Beckmann, H. S. G., & Spring, D. R. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35023h · Cited by 434
2011: the immune hallmarks of cancer
Cavallo, F., De Giovanni, C., Nanni, P., Forni, G., & Lollini, P.-L. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0968-0 · Cited by 415
Improving de novo protein binder design with deep learning
Bennett, N. R., Coventry, B., Goreshnik, I., Huang, B., Allen, A., Vafeados, D., Peng, Y. P., Dauparas, J., Baek, M., Stewart, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38328-5 · Cited by 402
Sun, Y., Lau, S. Y., Lim, Z. W., Chang, S. C., Ghadessy, F., Partridge, A., & Miserez, A. (2022) · Nature Chemistry · doi:10.1038/s41557-021-00854-4 · Cited by 411
Monoclonal Antibodies for Cancer Therapy
(2012) · SpringerReference · doi:10.1007/springerreference_303431 · Cited by 393
Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352
Phage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
Giang, E., Dorner, M., Prentoe, J. C., Dreux, M., Evans, M. J., Bukh, J., Rice, C. M., Ploss, A., Burton, D. R., & Law, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114927109 · Cited by 346
Recent advances in mass spectrometry based clinical proteomics: applications to cancer research
Macklin, A., Khan, S., & Kislinger, T. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09283-w · Cited by 317
Oncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Rath, T., Baker, K., Dumont, J. A., Peters, R. T., Jiang, H., Qiao, S.-W., Lencer, W. I., Pierce, G. F., & Blumberg, R. S. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.834293 · Cited by 281
MMP-Responsive ‘Smart’ Drug Delivery and Tumor Targeting
Yao, Q., Kou, L., Tu, Y., & Zhu, L. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.003 · Cited by 280
Single‐Cell Analysis Using Droplet Microfluidics
Matuła, K., Rivello, F., & Huck, W. T. S. (2020) · Advanced Biosystems · doi:10.1002/adbi.201900188 · Cited by 277
Functional single-cell hybridoma screening using droplet-based microfluidics
Debs, B. E., Utharala, R., Balyasnikova, I. V., Griffiths, A. D., & Merten, C. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204514109 · Cited by 276
Nabel, G. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204186 · Cited by 271
Yang, H., Qin, C., Li, Y. H., Tao, L., Zhou, J., Yu, C. Y., Xu, F., Chen, Z., Zhu, F., & Chen, Y. Z. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1230 · Cited by 270
Immunogenetic Mechanisms Driving Norovirus GII.4 Antigenic Variation
Lindesmith, L. C., Beltramello, M., Donaldson, E. F., Corti, D., Swanstrom, J., Debbink, K., Lanzavecchia, A., & Baric, R. S. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002705 · Cited by 266
Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes
Isabwe, G. A. C., Garcia Neuer, M., de las Vecillas Sanchez, L., Lynch, D.-M., Marquis, K., & Castells, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.018 · Cited by 265
Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting
Zhu, F., Qin, C., Tao, L., Liu, X., Shi, Z., Ma, X., Jia, J., Tan, Y., Cui, C., Lin, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107336108 · Cited by 255
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Bates, A., & Power, C. A. (2019) · Antibodies · doi:10.3390/antib8020028 · Cited by 237
Fornelli, L., Srzentić, K., Huguet, R., Mullen, C., Sharma, S., Zabrouskov, V., Fellers, R. T., Durbin, K. R., Compton, P. D., & Kelleher, N. L. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b00984 · Cited by 150
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies
Cao, Y., Balthasar, J. P., & Jusko, W. J. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9332-2 · Cited by 161
Yin, R., & Pierce, B. G. (2024) · Protein Science · doi:10.1002/pro.4865 · Cited by 145
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
Almagro, J. C., Beavers, M. P., Hernandez‐Guzman, F., Maier, J., Shaulsky, J., Butenhof, K., Labute, P., Thorsteinson, N., Kelly, K., Teplyakov, A., et al. (2011) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.23130 · Cited by 131
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
Grevys, A., Nilsen, J., Sand, K. M. K., Daba, M. B., Øynebråten, I., Bern, M., McAdam, M. B., Foss, S., Schlothauer, T., Michaelsen, T. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03061-x · Cited by 98
Synthetic antibodies designed on natural sequence landscapes
Zhai, W., Glanville, J., Fuhrmann, M., Mei, L., Ni, I., Sundar, P. D., Van Blarcom, T., Abdiche, Y., Lindquist, K., Strohner, R., et al. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.07.018 · Cited by 93
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Ito, M. K., & Santos, R. D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.766 · Cited by 59
Vaisman-Mentesh, A., Rosenstein, S., Yavzori, M., Dror, Y., Fudim, E., Ungar, B., Kopylov, U., Picard, O., Kigel, A., Ben-Horin, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02921 · Cited by 54
In Vivo Fluorescence Imaging of IgG1 Aggregates After Subcutaneous and Intravenous Injection in Mice
Filipe, V., Que, I., Carpenter, J. F., Löwik, C., & Jiskoot, W. (2014) · Pharmaceutical Research · doi:10.1007/s11095-013-1154-9 · Cited by 39
Kumar, S., Mitchell, M. A., Rup, B., & Singh, S. K. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23169 · Cited by 33
Li, B., Fouts, A. E., Stengel, K., Luan, P., Dillon, M., Liang, W.-C., Feierbach, B., Kelley, R. F., & Hötzel, I. (2014) · mAbs · doi:10.4161/mabs.27875 · Cited by 28
“Natural human antibodies, derived from donors or transgenic mice, and humanized antibodies are the major source of therapeutic antibodies.(1) The advantage of these antibodies over antibodies obtained from phage or yeast or mammalian display libraries is that affinity maturation occurs in vivo through the process of s…”
BackgroundProduction of recombinant immunotherapeutics for anticancer treatment: The role of bioengineering
Pranchevicius, M.-C. S., & Vieira, T. R. (2013) · Bioengineered · doi:10.4161/bioe.24666 · Cited by 24
Development of scoring functions for antibody sequence assessment and optimization
Seeliger, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076909 · Cited by 24
Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction
Tavori, H., Melone, M., & Rashid, S. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.954551 · Cited by 21
Pai, R., Ma, N., Connor, A. V., Danilenko, D. M., Tarrant, J. M., Salvail, D., Wong, L., Hartley, D. P., Misner, D., Stefanich, E., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw037 · Cited by 9
Liu, C., Kim, Y. S., Lowe, J. H.-N., & Chung, S. (2021) · Bioanalysis · doi:10.4155/bio-2021-0099 · Cited by 8
Yang, W., & Lee, S. (2025) · Clinical and Translational Science · doi:10.1111/cts.70135 · Cited by 2
Learning antibody sequence constraints from allelic inclusion
Jagota, M., Hsu, C., Mazumder, T., Sung, K., DeWitt, W. S., Listgarten, J., Matsen, F. A., Ye, C. J., & Song, Y. S. (2024) · doi:10.1101/2024.10.22.619760 · Cited by 2
“Antibodies are also of interest as experimental tools and therapeutics, because they can be engineered to bind desired targets [3].”
BackgroundLearning antibody sequence constraints from allelic inclusion
Jagota, M., Hsu, C., Mazumder, T., Sung, K., DeWitt, W. S., Listgarten, J., Matsen IV, F. A., Ye, C. J., & Song, Y. S. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101368 · Cited by 2
Metadata
- Authors
- Nelson, A. L., Dhimolea, E., & Reichert, J. M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-09-03
- Volume
- 9
- Issue
- 10
- Pages
- 767-774
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2065303540
- Cited by
- 1,026
- References
- 50
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.